Increase of anti-metastatic efficacy by selectivity-but not affinity-optimization of synthetic serine protease inhibitors

Biological Chemistry

Volumn 384, Issue 10-11, 2003, Pages 1515-1525

  Banke, Ingo J ^a   Arlt, Matthias J E ^a   Pennington, Caroline ^b   Kopitz, Charlotte ^a   Steinmetzer, Torsten ^c   Schweinitz, Andrea ^d   Gansbacher, Bernd ^a   Quigley, James P ^e   Edwards, Dylan R ^b   Stürzebecher, Jörg ^d   Krüger, Achim ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c Curacyte Chemistry GmbH   (Germany)

^d Klinikum der Universitat Jena   (Germany)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Factor xa; Inhibitor selectivity; Lymphoma; Metastasis; Small molecule serine protease inhibitors; uPA

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; BENZYLAMINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CJ 435; CJ 441; CJ 502; CJ 503; CJ 504; CJ 510; CJ 513; PLASMINOGEN ACTIVATOR INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; IN VIVO STUDY; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTITHROMBIN III; BENZYLAMINES; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; LIVER NEOPLASMS; LYMPHOMA, T-CELL; MATRIX METALLOPROTEINASES; MICE; NEOPLASM METASTASIS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY PLASMINOGEN ACTIVATOR;

ANIMALIA; MURINAE;

EID: 0346245137     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2003.168     Document Type: Article

References (51)

1. Arlt, M., Kopitz, C., Pennington, C., Watson, K.L., Krell, H.W., Bode, W., Gansbacher, B., Khokha, R., Edwards, D.R., and Krüger, A. (2002). Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res. 62, 5543-5550.
2. Chambers, A.F. and Matrisian, L.M. (1997). Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89, 1260-1270.
3. Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392.
4. Davie, E.W., Fujikawa, K., and Kisiel, W. (1991). The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363-10370.
5. DeClerck, Y.A., Imren, S., Montgomery, A.M., Mueller, B.M., Reisfeld, R.A., and Laug, W.E. (1997). Proteases and protease inhibitors in tumor progression. Adv. Exp. Med. Biol. 425, 89-97.
6. Donnelly, K.M., Bromberg, M.E., Milstone, A., Madison McNiff, J.M., Terwilliger, G., Konigsberg, W.H., and Cappello, M. (1998). Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro. Thromb. Haemost. 79, 1041-1047.
7. Dyke, C.K., Becker, R.C., Kleiman, N.S., Hochman, J.S., Bovill, E.G., Lincoff, A.M., Gerstenblith, G., Dzavik, V., Gardner, L.H., Hasselblad, V. et al. (2002). First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 105, 2385-2391.
8. Edwards, D.R., Leco, K.J., Beaudry, P.P., Atadja, P.W., Veillette, C., and Riabowol, K.T. (1996). Differential effects of transforming growth factor-β 1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts. Exp. Gerontol. 31, 207-223.
9. Egeblad, M. and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161-174.
10. Francis, J.L., Biggerstaff, J., and Amirkhosravi, A. (1998). Hemostasis and malignancy. Semin. Thromb. Hemost. 24, 93-109.
11. Friedrich, R., Fuentes-Prior, P., Ong, E., Coombs, G., Hunter, M., Oehler, R., Pierson, D., Gonzalez, R., Huber, R., Bode, W., and Madison, E.L. (2002). Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J. Biol. Chem. 277, 2160-2168.
12. Glynn, O. (2003). The express study: preliminary results. Int. J. Clin. Prac. 57, 57-59.
13. Guo, Y., Higazi, A.A., Arakelian, A., Sachais, B.S., Cines, D., Goldfarb, R.H., Jones, T.R., Kwaan, H., Mazar, A.P., and Rabbani, S.A. (2000). A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 14, 1400-1410.
14. Hahn-Dantona, E., Ramos-DeSimone, N., Sipley, J., Nagase, H., French, D.L., and Quigley, J.P. (1999). Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann. NY Acad. Sci. 878, 372-387.
15. Harbeck, N., Alt, U., Berger, U., Krüger, A., Thomssen, C., Janicke, F., Hofler, H., Kates, R.E., and Schmitt, M. (2001). Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin. Cancer Res. 7, 2757-2764.
16. Hauptmann, J. and Stürzebecher, J. (1999). Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb. Res. 93, 203-241.
17. Hauptmann, J., Steinmetzer, T., Vieweg, H., Wikstrom, P., and Stürzebecher, J. (2002). Influence of structural variations in peptidomimetic 4-amidinophenylalanine-derived thrombin inhibitors on plasma clearance and biliary excretion in rats. Pharm. Res. 19, 1027-1033.
18. Hidalgo, M. and Eckhardt, S.G. (2001). Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93, 178-193.
19. Hooper, J.D., Clements, J.A., Quigley, J.P., and Antalis, T.M. (2001). Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 276, 857-860.
20. Ihara, S., Miyoshi, E., Ko, J.H., Murata, K., Nakahara, S., Honke, K., Dickson, R.B., Lin, C.Y., and Taniguchi, N. (2002). Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1-6 GlcNAc branching. J. Biol. Chem. 277, 16960-16967.
21. Inuzuka, K., Ogata, Y., Nagase, H., and Shirouzu, K. (2000). Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J. Surg. Res. 93, 211-218.
22. Koblinski, J.E., Ahram, M., and Sloane, B.F. (2000). Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135.
23. Kossakowska, A.E., Urbanski, S.J., Huchcroft, S.A., and Edwards, D.R. (1992). Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Oncol. Res. 4, 233-240.
24. Kossakowska, A.E., Urbanski, S.J., and Janowska-Wieczorek, A. (2000). Matrix metalloproteinases and their tissue inhibitors-expression, role and regulation in human malignant non-Hodgkin's lymphomas. Leuk. Lymphoma 39, 485-493.
25. Krüger, A., Schirrmacher, V., and von Hoegen, P. (1994). Scattered micrometastases visualized at the single-cell level: detection and re-isolation of lacZ-labeled metastasized lymphoma cells. Int. J. Cancer 58, 275-284.
26. Krüger, A., Fata, J.E., and Khokha, R. (1997). Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 90, 1993-2000.
27. Krüger, A., Soeltl, R., Sopov, I., Kopitz, C., Arlt, M., Magdolen, V., Harbeck, N., Gansbacher, B., and Schmitt, M. (2001). Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res. 61, 1272-1275.
28. Künzel, S., Schweinitz, A., Reissmann, S., Stürzebecher, J., and Steinmetzer, T. (2002). 4-Amidinobenzylamine-based inhibitors of urokinase. Bioorg. Med. Chem. Lett. 12, 645-648.
29. Lah, T.T. and Kos, J. (1998). Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379, 125-130.
30. Lah, T.T., Strojnik, T., Levicar, N., Bervar, A., Zajc, I., Pilkington, G., and Kos, J. (2000). Clinical and experimental studies of cysteine cathepsins and their inhibitors in human brain tumors. Int. J. Biol. Markers 15, 90-93.
31. Leadley, R.J., Jr., Chi, L., and Porcari, A.R. (2001). Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. Curr. Opin. Pharmacol. 1, 169-175.
32. Look, M.P., van Putten, W.L., Duffy, M.J., Harbeck, N., Christensen, I.J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S. et al. (2002). Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 94, 116-128.
33. Magdolen, V., Arroyo de Prada, N., Sperl, S., Muehlenweg, B., Luther, T., Wilhelm, O.G., Magdolen, U., Graeff, H., Reuning, U., and Schmitt, M. (2000). Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv. Exp. Med. Biol. 477, 331-341.
34. Nagahara, T., Yokoyama, Y., Inamura, K., Katakura, S., Komoriya, S., Yamaguchi, H., Hara, T., and Iwamoto, M. (1994). Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J. Med. Chem. 37, 1200-1207.
35. Noel, A., Gilles, C., Bajou, K., Devy, L., Kebers, F., Lewalle, J.M., Maquoi, E., Munaut, C., Remacle, A., and Foidart, J.M. (1997). Emerging roles for proteinases in cancer. Invasion Metastasis 17, 221-239.
36. Oberst, M., Anders, J., Xie, B., Singh, B., Ossandon, M., Johnson, M., Dickson, R.B., and Lin, C.Y. (2001). Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol. 158, 1301-1311.
37. Oberst, M.D., Johnson, M.D., Dickson, R.B., Lin, C.Y., Singh, B., Stewart, M., Williams, A., al-Nafussi, A., Smyth, J.F., Gabra, H., and Sellar, G.C. (2002). Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res. 8, 1101-1107.
38. Overall, C.M. and Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer 2, 657-672.
39. Rabbani, S.A., Harakidas, P., Davidson, D.J., Henkin, J., and Mazar, A.P. (1995). Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer 63, 840-845.
40. Rabbani, S.A. and Mazar, A.P. (2001). The role of the plasminogen activation system in angiogenesis and metastasis. Surg. Oncol. Clin. N. Am. 10, 393-415.
41. Reuning, U., Magdolen, V., Wilhelm, O., Fischer, K., Lutz, V., Graeff, H., and Schmitt, M. (1998). Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol. 13, 893-906.
42. Reuning, U., Magdolen, V., Hapke, S., and Schmitt, M. (2003). Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol. Chem. 384, 1119-1131.
43. Rockway, T.W., Nienaber, V., and Giranda, V.L. (2002). Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr. Pharm. Des. 8, 2541-2558.
44. Sampson, M.T. and Kakkar, A.K. (2002). Coagulation proteases and human cancer. Biochem. Soc. Trans. 30, 201-207.
45. Sanderson, P.E. (1999). Small, noncovalent serine protease inhibitors. Med. Res. Rev. 19, 179-197.
46. Stürzebecher, J., Prasa, D., Hauptmann, J., Vieweg, H., and Wikstrom, P. (1997). Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J. Med. Chem. 40, 3091-3099.
47. Tsirka, S.E. (2002). Tissue plasminogen activator as a modulator of neuronal survival and function. Biochem. Soc. Trans. 30, 222-225.
48. Walsh, P.N. and Ahmad, S.S. (2002). Proteases in blood clotting. Essays Biochem. 38, 95-111.
49. Zacharski, L.R., Memoli, V.A., and Rousseau, S.M. (1986). Coagulation-cancer interaction in situ in renal cell carcinoma. Blood 68, 394-399.
50. Zacharski, L.R., Memoli, V.A., Rousseau, S.M., and Kisiel, W. (1987). Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung. Cancer 60, 2675-2681.
51. Zucker, S., Cao, J., and Chen, W.T. (2000). Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-6650.